Q32 Bio Inc. (QTTB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Q32 Bio Inc. (QTTB) Healthcare & Pipeline Overview

Q32 Bio Inc. is a clinical-stage biotechnology company specializing in biologic therapeutics for autoimmune and inflammatory diseases. Its pipeline features ADX-097, targeting complement-mediated diseases, and Bempikibart (ADX-914), currently in Phase II trials for dermatological conditions, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for QTTB?

Q32 Bio Inc. presents a focused investment opportunity within the biotechnology sector, driven by its clinical-stage pipeline targeting autoimmune and inflammatory diseases. Key value drivers include the successful advancement of ADX-097 through clinical trials for complement-mediated diseases and the progression of Bempikibart (ADX-914) in Phase II trials for dermatological conditions. The company's high gross margin of 99.5% indicates strong potential profitability upon commercialization. Upcoming clinical trial results for both ADX-097 and Bempikibart serve as potential catalysts. However, the company's relatively small market capitalization of $0.07 billion and negative beta of -1.02 suggest higher volatility and sensitivity to market downturns. Successful navigation of regulatory hurdles and securing partnerships will be crucial for long-term growth.

Based on FMP financials and quantitative analysis

QTTB Key Highlights

Market capitalization of $0.07 billion, reflecting its position as a smaller player in the biotechnology industry.

• P/E ratio of 3.84, suggesting potential undervaluation relative to earnings.
• Profit margin of 61.9%, indicating strong profitability from its operations.
• Gross margin of 99.5%, highlighting efficient cost management in its research and development activities.
• Beta of -1.02, suggesting an inverse correlation with the market, potentially offering diversification benefits.

Who Are QTTB's Competitors?

QTTB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are QTTB's Key Strengths?

Innovative pipeline of biologic therapeutics.

• Focus on high unmet medical needs.
• High gross margin.
• Experienced management team.

What Are QTTB's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on successful clinical trial outcomes.
• Limited financial resources.
• Small market capitalization.

What Could Drive QTTB Stock Higher?

Clinical trial results for ADX-097 in complement-mediated diseases.

• Clinical trial results for Bempikibart (ADX-914) in atopic dermatitis and alopecia areata.
• Potential for strategic partnerships with larger pharmaceutical companies.
• Advancements in the development of their proprietary technology platform.

What Are the Key Risks for QTTB?

Failure to obtain regulatory approval for ADX-097 and Bempikibart.

• Competition from established pharmaceutical companies with greater resources.
• Patent expiration and the emergence of biosimilar competition.
• Adverse events or unexpected safety concerns in clinical trials.
• Dependence on securing additional funding to support ongoing research and development activities.

What Are the Growth Opportunities for QTTB?

• Advancement of ADX-097 for Complement-Mediated Diseases: ADX-097, Q32 Bio's lead product candidate, targets a range of complement-mediated diseases, including lupus nephritis and IgA nephropathy. Successful completion of clinical trials and regulatory approval could drive significant revenue growth, positioning Q32 Bio as a key player in this therapeutic area. Timeline for potential market entry is dependent on clinical trial outcomes and regulatory review.
• Development of Bempikibart (ADX-914) for Atopic Dermatitis and Alopecia Areata: Bempikibart is currently in Phase II clinical trials for atopic dermatitis and alopecia areata. The atopic dermatitis market is expected to grow substantially, driven by increasing prevalence and unmet needs. Positive clinical trial results and subsequent regulatory approval could open up a significant market opportunity for Q32 Bio. The timeline for commercialization depends on the success of ongoing trials and regulatory processes.
• Expansion of Pipeline through Strategic Partnerships and Acquisitions: Q32 Bio can expand its pipeline by in-licensing or acquiring promising drug candidates or technologies. Strategic partnerships with other biotechnology or pharmaceutical companies can provide access to new therapeutic areas and accelerate the development of existing programs. This approach can diversify the company's risk profile and create new growth opportunities. The timing and success of such initiatives are contingent on market conditions and available opportunities.
• Geographic Expansion Beyond the United States: Currently, Q32 Bio operates primarily in the United States. Expanding into international markets, such as Europe and Asia, could significantly increase its addressable market. This expansion would require navigating different regulatory environments and establishing partnerships with local distributors or pharmaceutical companies. The timeline for international expansion depends on the company's strategic priorities and available resources.
• Leveraging Proprietary Technology Platform for New Drug Discovery: Q32 Bio's expertise in developing biologic therapeutics for autoimmune and inflammatory diseases can be leveraged to discover and develop new drug candidates. By utilizing its proprietary technology platform, the company can identify novel targets and develop innovative therapies for unmet medical needs. This approach can create a sustainable pipeline of new products and drive long-term growth. The success of this strategy depends on the company's research and development capabilities and its ability to identify promising new targets.

What Are QTTB's Competitive Advantages?

• Proprietary technology platform for developing biologic therapeutics.
• Strong intellectual property protection for their drug candidates.
• Clinical trial data demonstrating the safety and efficacy of their therapies.
• Expertise in targeting complement-mediated diseases and dermatological conditions.

What Does QTTB Do?

Founded in 2017 and based in Waltham, Massachusetts, Q32 Bio Inc. is dedicated to restoring healthy immune balance in patients suffering from autoimmune and inflammatory diseases. Originally named AdMIRx Inc., the company rebranded in April 2020 to Q32 Bio Inc. The company focuses on addressing pathological immune dysfunction through the development of biologic therapeutics. Their lead product candidate, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to restore complement regulation. ADX-097 has completed Phase I clinical trials and is being developed for renal and other complement-mediated diseases with high unmet needs, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Q32 Bio is also advancing Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody. Bempikibart aims to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin. This product is currently in Phase II clinical trials for the treatment of atopic dermatitis and alopecia areata. Q32 Bio operates primarily in the United States.

What Products and Services Does QTTB Offer?

• Develop biologic therapeutics for autoimmune and inflammatory diseases.
• Focus on restoring healthy immune balance in patients.
• Advance ADX-097, a humanized anti-C3d monoclonal antibody fusion protein, for complement-mediated diseases.
• Develop Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody, for atopic dermatitis and alopecia areata.
• Conduct Phase I and Phase II clinical trials to evaluate the safety and efficacy of their drug candidates.
• Target diseases with high unmet medical needs, such as lupus nephritis and IgA nephropathy.

How Does QTTB Make Money?

• Develop and commercialize biologic therapeutics.
• Generate revenue through the sale of approved drugs.
• Out-license or partner with other companies for drug development and commercialization.
• Secure funding through venture capital, public offerings, and grants.

What Industry Does QTTB Operate In?

Q32 Bio Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for autoimmune and inflammatory disease therapeutics is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Key trends include the development of novel biologic therapies and personalized medicine approaches. Q32 Bio's focus on complement-mediated diseases and dermatological conditions positions it within specific niches of this broader market, competing with both large pharmaceutical companies and smaller biotech firms.

Who Are QTTB's Key Customers?

• Patients with autoimmune and inflammatory diseases.
• Healthcare providers who prescribe and administer their drugs.
• Hospitals and clinics that use their therapies.
• Pharmaceutical companies that may partner with them for drug development and commercialization.

Q32 Bio Inc. Financial Trajectory

Q32 Bio Inc. (QTTB) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $8.9M, with diluted EPS of $-0.63. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, QTTB averaged $0.65 in diluted EPS.

Company Profile

Q32 Bio Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Jodie Pope Morrison. QTTB has traded publicly since 2018.

How Q32 Bio Inc. Is Valued

Analyst price targets span from $14.00 to $66.00, with a consensus of $38.00. At the current price of $10.93, that implies approximately 248% upside potential. Relative to its peer group, QTTB's quantitative score of 68/100 is below the peer average of 89/100.

Return on equity for Q32 Bio Inc. stands at 230.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 52.2%, showing how much profit it generates from its asset base. QTTB trades at a trailing price-to-earnings ratio of 3.84, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -17.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 19.7%, the inverse of the P/E and a quick read on earnings relative to price.

Q32 Bio Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 19.81 places it in the safe zone, indicating low near-term bankruptcy risk.

Q32 Bio Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 84.2% above estimates on average.

Over the past six months, Q32 Bio Inc. insiders filed 28 SEC Form 4 transactions — 4 sales and 24 purchases. On net that is roughly 4.1M shares acquired (about $31.8M) — insiders putting money in tends to read as conviction.

QTTB Financials

QTTB Latest News

QTTB Analyst Consensus

QTTB MoonshotScore

Latest Q32 Bio Inc. Analysis

What Investors Ask About Q32 Bio Inc. (QTTB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources